biolitec AG achieved consolidated revenue of Euro 35.4 million for the fiscal year 2007/2008 -expectation of sales growth to resume in this fiscal year

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

Jena (euro adhoc) - Jena, September 30, 2008 - biolitec AG, Jena, listed in the
Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409) posted a
consolidated revenue of Euro 35.4 million for the fiscal year 2007/2008. Mainly
contributing to this were the business segments urology laser, vein treatment
and laser liposuction.

The revenue was 9% lower than in the prior year due to the unfavourable
investment climate in the USA, its impact on the investment cycle and the
unfavourable dollar exchange rate. In the USA biolitec AG is market leader in
the sector of ambulant therapy of the benign prostate hyperplasia (BPH). More
than 600 US urologists already have applied LIFE™ laser therapy, about 200 as
in-office treatment. At the 2008 American Urological Association´s (AUA)
National Scientific Meeting in Orlando/Florida US urologists were keen on the
gentle in-office treatment with biolitec´s laser Evolve™ 150 and the short
treatment time.

R&D expenditures for the fiscal year 2007/2008 of Euro 5.1 million (14% of
sales) remained at a high level to ensure the groups long term growth and
profitability. Net income amounted to about Euro 2 million despite the
continuous high R&D investments as well as the decline in sales. The gross
profit amounted to about Euro 24 million and EBIT amounted to Euro 1.4 million.

For example biolitec has just revolutionized endovenous laser treatment for
varicose veins by the application of the new, innovative laser fiber ELVeS®
RADIAL, which emits the light radially.

The revenue posted by the laser segment of Euro 12.1 million was lower than in
the prior year mainly due to the market decline in the USA. The fiber optics and
laser probes segment contributed to about Euro 22 million to the group´s total
revenue. Mainstays of sales are the LIFE™ BPH laser treatment and the
Endoluminal Laser Treatment of Veins (ELVeS™).

The urology laser Evolve™ 150 is rising further in the estimation of physicians
and the number of LIFE™ laser treatment centres is increasing continuously. In
Germany the outpatient treatment of BPH with the Evolve™ laser is gaining
ground. The biolitec AG has recently introduced the first 300 watt urology laser
to the German market.

biolitec´s major revenues were again generated in Europe and North America. With
Euro 14.7 million, sales in North America were 22% lower than previous year´s
sales contributing 42% of total sales. European sales amounted to Euro 17.9
million (previous year 17.8%).

Dr. Wolfgang Neuberger, CEO of biolitec AG: "We proceed on the assumption that
the demand on gentle urology therapies as well as treatments in the field of
aesthetics will further increase and the market caution will decrease. Due to
our excellent market position in Europe and North America we expect an increase
in turnover and profit in the current fiscal year even driven by the
expenditures of transacted research and development."

About biolitec
biolitec is the only supplier for photodynamic therapy worldwide that offers all
relevant core competencies - photosensitizers, lasers and optical fibers.
Besides minimal invasive laser treatments and the oncology business biolitec has
successfully developed competencies in the field of aesthetics. biolitec is
listed in the Prime Standard under ISIN DE0005213409. For more information:
www.biolitec.com.

Further inquiry note:
Press contact
Jörn Gleisner
Telefon : +49 (0) 69 / 959083-20
Telefax : +49 (0) 69 / 959083-99
E-Mail: [email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: biolitec AG
Winzerlaer Straße 2a
D-07745 Jena
phone: +49 (0)3641 5 08-5 50
FAX: +49 (0)3641 5 08-5 99
mail: [email protected]
WWW: www.biolitec.de
sector: Pharmaceuticals
ISIN: DE0005213409
indexes: CDAX, Prime All Share, Technologie All Share
stockmarkets: regulated dealing/prime standard: Börse Frankfurt, free trade:
Börse Berlin, Börse Hamburg, Börse Stuttgart, Börse Düsseldorf,
Börse München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print